| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 795,950 | 0 | - | 389,276 |
| Cost of revenues | - | 0 | - | 296 |
| Gross (loss) profit | 795,950 | 0 | - | 388,980 |
| Selling, general and administrative expenses | 798,253 | 690,094 | 615,371 | 301,208 |
| Research and development expenses | 29,890 | 33,276 | 28,861 | 37,825 |
| Stock-based compensation | 1,136,217 | 1,571,613 | 48,773 | - |
| Total operating expenses | 1,964,360 | 2,294,983 | 693,005 | 339,033 |
| Operating sublease income | - | 12,000 | - | 12,000 |
| Loss from operations | -1,168,410 | -2,294,983 | -693,005 | 49,947 |
| Interest income | 47,287 | 19,139 | 19,071 | 44,261 |
| Interest expense | 30,959 | 129,413 | 222,967 | 219,533 |
| Operating sublease income | 29,680 | - | 12,000 | - |
| Gain (loss) on foreign exchange | -112,553 | 136,148 | -9,912 | 30,429 |
| Loss on investment in equity securities | -54,235 | -44,917 | -50,877 | -67,885 |
| Other income (expenses) | 2,194 | -7,180 | 1,500 | 16,864 |
| Total other income (expenses) | -118,586 | -14,223 | -251,185 | -183,864 |
| Loss before provision income tax | -1,286,996 | -2,309,206 | -944,190 | -133,917 |
| Provision for income tax expense | 527 | 23,627 | - | 355 |
| Net loss | -1,287,523 | -2,332,833 | -944,190 | -134,272 |
| Net loss attributable to noncontrolling interests | -41,010 | -75,811 | -102,115 | 52,289 |
| Net loss attributed to abvc and subsidiaries | -1,246,513 | -2,257,022 | -842,075 | -186,561 |
| Foreign currency translation adjustment | 3,236 | 39,640 | -1,493 | 25,389 |
| Comprehensive loss | -1,243,277 | -2,217,382 | -843,568 | -161,172 |
| Basic (in dollars per share) | -0.05 | -0.13 | -0.06 | -0.02 |
| Basic (in shares) | 23,256,590 | 17,386,536 | 14,968,232 | 12,405,261 |
| Diluted (in dollars per share) | -0.05 | -0.13 | -0.06 | -0.02 |
| Diluted (in shares) | 23,256,590 | 17,386,536 | 14,968,232 | 12,405,261 |
ABVC BIOPHARMA, INC. (ABVC)
ABVC BIOPHARMA, INC. (ABVC)